Hancock Whitney’s Pacira BioSciences PCRX Stock Holding History

Hancock Whitney’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,615	Closed	-$229K	–	650
2023 Q1	$229K	Sell	5,615 -756	-12%	-$30.1K	0.01%	593
2022 Q4	$246K	Sell	6,371 -75	-1%	-$3.65K	0.01%	568
2022 Q3	$343K	Buy	6,446 +944	+17%	+$52.5K	0.01%	493
2022 Q2	$321K	Sell	5,502 -233	-4%	-$15.3K	0.01%	529
2022 Q1	$438K	Sell	5,735 -1,271	-18%	-$84.7K	0.01%	501
2021 Q4	$422K	Sell	7,006 -51	-0.7%	-$2.81K	0.01%	514
2021 Q3	$395K	Buy	7,057 +41	+0.6%	+$2.36K	0.01%	525
2021 Q2	$426K	Sell	7,016 -150	-2%	-$9.49K	0.01%	598
2021 Q1	$502K	Sell	7,166 -116	-2%	-$8.29K	0.02%	547
2020 Q4	$436K	Sell	7,282 -27	-0.4%	-$1.58K	0.01%	566
2020 Q3	$439K	Buy	7,309 +285	+4%	+$16.6K	0.02%	537
2020 Q2	$369K	Sell	7,024 -2,625	-27%	-$110K	0.01%	575
2020 Q1	$324K	Buy	+9,649	New	+$401K	0.01%	618

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hancock Whitney's PCRX Position: Q2 2023 in Review

Hancock Whitney sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 5,615 shares — an estimated $229K sold.

Hancock Whitney first reported a position in PCRX in Q1 2020 and held it in 13 quarters. The position peaked at $502K in Q1 2021. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

Hancock Whitney reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
Hancock Whitney sold 5,615 Pacira BioSciences shares in Q2 2023, an estimated $229K.
Hancock Whitney first reported a position in Pacira BioSciences in Q1 2020 and held it in 13 quarters.
Hancock Whitney's Pacira BioSciences position peaked at $502K in Q1 2021.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Hancock Whitney's 13F filing for Q2 2023, filed 10 Aug 2023.